Antibody Ingredients TRIZ Cases

Targeting high EGFR expression with an antibody improves survival in patients who progressed after immune checkpoint inhibitor treatment.

Combining anti-PD-1 antibodies with radiation therapy overcomes Hedgehog Inhibitor resistance and expands treatment options for unresectable skin cancer.

Engineered humanized and bispecific antibodies reduce liver toxicity while enhancing anti-tumor efficacy through localized CD40 activation.

Fully human monoclonal antibodies bind mesothelin with high affinity to enable targeted cancer detection and treatment.

Extending natalizumab dosing intervals to six to eight weeks reduces progressive multifocal leukoencephalopathy risk while maintaining therapeutic efficacy.

Monoclonal antibodies bind distinct HER2 epitopes to enhance internalization and cytotoxicity.

Novel bispecific binding agents combine knobs-in-holes dimerization with single-chain Fab formats to target IL-6Rα and IL-8R receptors simultaneously.

Merges three checkpoint inhibitors into one injection to reduce regimen complexity while maintaining immune activation through optimized buffer chemistry.

Targeted mutations in the antibody Fc region eliminate complement activation and thrombogenic reactions while preserving therapeutic efficacy.

A humanized monoclonal antibody binds to the ICOS receptor on T cells to stimulate proliferation and cytokine release.

Circular fusion polypeptides create trivalent binding sites, reducing molecular weight while maintaining high affinity and specificity.

Periodic administration of a bispecific CD33-CD3 antibody eliminates myeloid leukemia while allowing the myeloid compartment to recover from toxicity.

A multifunctional antibody conjugate links an anti-IGF1R antibody to an Ang2-binding peptide via a specific linker.

An antibody specifically binds to B7-H3 IgC1 and IgC2 domains to trigger immune-mediated tumor cell destruction.

Genetic testing identifies wild-type STK11 status to guide anti-PD-1 antibody administration, bypassing chemotherapy resistance in non-small cell lung cancer.

Combining GPER agonist G-1 with anti-PD-1 antibody overcomes limited clinical efficacy by inducing cellular differentiation in melanoma cells.

Sequential administration of anti-CEACAM1 and anti-PD-1 antibodies resolves efficacy complexity trade-offs by synergistically attenuating tumor progression.

Fully human antibodies target IL-1RAcP domain 2, blocking IL-1, IL-33, and IL-36 signaling while eliminating antibody-dependent cellular cytotoxicity.

Non-blocking CCR8 binders deplete tumour-infiltrating regulatory T-cells via ADCC, preserving peripheral Tregs and reducing systemic side effects.

Antibodies targeting the DSL domain of Jagged 1 inhibit tumour growth while reducing gastrointestinal toxicity associated with pan-Notch inhibition.

A non-competitive anti-FcRn antibody reduces pathogenic auto-antibodies without competing with IgG, lowering required doses and side effects.

Antibodies use human framework grafting to reduce serum sickness while maintaining binding effectiveness for cancer therapy.

Anti-CD277 monoclonal antibodies relieve BTN3A1-mediated suppression of gamma delta T cells, enabling anti-tumor immune responses without phosphoantigens.

Administering an ICOS agonist to treat cancer by measuring ICOS and T-bet levels in CD4+ T cells.

A multicellular targeting liposome displays multiple antibodies to bind diverse cell types simultaneously.

Merging BCMA and TACI targeting into one molecule prevents antigen loss while maintaining sustained efficacy against multiple myeloma.

Segmenting monoclonal antibodies into smaller ISVDs improves tumor penetration while reducing manufacturing costs.

Segmented multi-specific binding proteins bridge NK cells and HER2 targets, resolving the trade-off between enhanced cytotoxicity and healthy cell safety.

A concentrated immunoglobulin G formulation uses glycine and nonionic detergents to maintain high protein stability.

Sequence modification eliminates the hook effect, ensuring reliable therapeutic efficacy across varying antibody concentrations.

Opposite charged mutations in VL, VH, CH1, and CL regions resolve production inefficiency from asymmetric chain mispairing.

BCMA-specific antibody drug conjugates localize cytotoxic agents on myeloma surfaces, reducing toxicity to non-target tissues.

Anti-PD-1 antibody treatment extends progression-free survival in urothelial carcinoma patients relapsing after platinum-based chemotherapy.

Targeting FcRn with IgG variants or inhibitors regulates IL-12 levels, resolving the trade-off between anti-tumor immunity and autoimmune risk.

Anti-ILT5 antibodies block inhibitory signals on antigen-presenting cells to enhance T cell proliferation while preventing excessive immune activation.

ENTPD2-specific antibodies bind to the target enzyme to block its catalytic function, reducing inflammation and tumor progression in cancer treatment.

BCD-135 monoclonal antibody targets PD-L1 using specific amino acid sequences to overcome limited efficacy in current immunotherapies.

Humanized anti-VSIG4 antibodies bind VSIG4 receptors on M2 macrophages to induce conversion into M1 phenotype.

Combining anti-LAG-3 and anti-PD-1 antibodies overcomes immune tolerance in advanced solid tumors.

Polypeptide stabilizes CD11b/CD18 integrins to prevent fibrosis and kidney failure after ischemia reperfusion injury.

Bispecific antibodies bind distinct HER2 epitopes to overcome resistance in low-expression tumors.

An anti-TG2 antibody blocks transglutaminase 2 transamidase activity to inhibit protein crosslinking in lung tissue.

A CD38 antibody binds target protein with high specificity to induce cytotoxic cell death mechanisms.

Anti-PD-1 antibody administration improves progression-free survival in patients with microsatellite instability-high colorectal cancer.

Modified IgG1 antibodies resist soluble CEA blocking to maintain cytotoxic activity against epithelial tumors.

Segmented antibody-drug conjugates deliver cytotoxic payloads specifically to EGFR-expressing cells, reducing side effects on normal tissues.